Is IGF-I receptor a target for autoantibody generation in graves' disease?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 515-518

  Smith, Terry J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HYALURONIC ACID; IMMUNOGLOBULIN G; IODINE 125; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P70; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; THYROID ANTIBODY; THYROTROPIN RECEPTOR;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIGEN DETECTION; AUTOPHOSPHORYLATION; DISEASE ASSOCIATION; DISEASE SEVERITY; GRAVES DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; OUTCOME ASSESSMENT; PATHOGENICITY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

AUTOANTIBODIES; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTOR, IGF TYPE 1;

EID: 84873641735     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1004     Document Type: Review

References (21)

1. Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008; 358:2594-2605.
2. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
3. Feliciello A, Porcellini A, Ciullo I, Bonavolontà G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet. 1993;342:337-338.
4. Gerding MN, van der Meer JW, Broenink M, Bakkar O, Wiersinga W, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000;52:267-271.
5. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-3470.
6. Tao TW, Cheng PJ, Pham H, Leu SL, Kriss JP. Monoclonal antithyroglobulin antibodies derived from immunizations of mice with human eye muscle and thyroid membranes. J Clin Endocrinol Metab. 1986;63:577-582.
7. Smith TJ. Insulin like growth factor-1 regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199-236.
8. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16:251-257.
9. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942-950.
10. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003; 170:6348-6354.
11. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076-5080.
12. van Zeijl CJ, Fliers E, van Koppen CJ, et al. Thyrotropin receptorstimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid. 2011;21:169-176.
13. Minich WB, Dehina N, Welsink T, et al. Autoantibodies to the IGF1-receptor in Graves' orbitopathy. J Clin Endocrinol Metab. 2013;98:752-760.
14. Varewijck AJ, Boelen A, Lamberts SW, et al. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2013;98: 769-776.
15. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824-854.
16. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulinlike growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphateβ and the IGF-I receptor to regulate IGF-I-stimulating signaling. Mol Cell Biol. 2012;32:4116-4130.
17. Santer F, Bacher N, Moser B, et al. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome- dependent proteolysis. Cancer Res. 2006;66: 3024-3033.
18. Schedlich LJ, Graham LD, O'Han MK, et al. Molecular basis of the interaction between IGFBP-3 and retinoid X receptor: role in modulation of RAR-signaling. Arch Biochem Biophys. 2007;465:359-369.
19. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008;181:4397-4405.
20. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab. 2012;97:1681-1687.
21. Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96:2386-2394.